Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
AngioDynamics ( (ANGO) ) has provided an update.
On January 6, 2026, AngioDynamics reported financial results for its fiscal second quarter ended November 30, 2025, highlighted by 8.8% year-on-year pro forma net sales growth to $79.4 million and the fifth consecutive quarter of double-digit growth in its Med Tech segment, which rose 13.0% to $35.7 million. Segment performance was driven by strong gains in Auryon, Mechanical Thrombectomy, and NanoKnife, contributing to an improved gross margin of 56.4%, a sharply reduced adjusted net loss of $0.1 million, and higher adjusted EBITDA of $5.9 million, while the company generated $4.7 million in cash, ended the quarter with $41.6 million in cash and no debt, and raised full-year fiscal 2026 guidance for net sales and adjusted EBITDA. Operationally, the quarter brought notable regulatory and strategic milestones, including FDA IDE approvals for the APEX-Return study of the AlphaReturn Blood Management System with AlphaVac in acute pulmonary embolism and for the PAVE study of AngioVac in right-sided infective endocarditis, as well as FDA 510(k) clearance expanding indications for the modified AlphaVac F1885 System, the successful conclusion of remaining patent litigation items with Bard, and the announcement that President and CEO Jim Clemmer will retire during fiscal 2027 as the board launches a search for his successor, developments that collectively strengthen the company’s mechanical thrombectomy franchise and underscore a pivotal leadership transition.
The most recent analyst rating on (ANGO) stock is a Buy with a $24.00 price target. To see the full list of analyst forecasts on AngioDynamics stock, see the ANGO Stock Forecast page.
Spark’s Take on ANGO Stock
According to Spark, TipRanks’ AI Analyst, ANGO is a Neutral.
The score reflects a strong balance sheet and improving operational trajectory highlighted by raised guidance and robust segment growth, but is held back by continued operating/net losses and negative operating/free cash flow. Technical indicators are broadly neutral and valuation support is limited by the negative P/E and no dividend.
To see Spark’s full report on ANGO stock, click here.
More about AngioDynamics
AngioDynamics, Inc., based in Latham, N.Y., is a medical technology company focused on restoring healthy blood flow in the vascular system, expanding cancer treatment options, and improving patients’ quality of life. Its Med Tech portfolio includes the Auryon peripheral atherectomy platform, thrombus management technologies such as AngioVac and AlphaVac, and the NanoKnife irreversible electroporation platform, complemented by a broader Med Device business.
Average Trading Volume: 452,763
Technical Sentiment Signal: Hold
Current Market Cap: $545.1M
See more data about ANGO stock on TipRanks’ Stock Analysis page.